COMMUNIQUÉS West-GlobeNewswire

Ambu A/S: Capital increase in connection with exercise of warrants issued
17/05/2018
In December 2013, Ambu A/S issued 2,000,000 warrants and in December 2014 2,000,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 52 individuals [...]
Additional Agenda Items of the AGM of AS Olainfarm to be Held on June 05, 2018
17/05/2018
Additional Agenda Items of the AGM of AS Olainfarm to be Held on June 05, 2018 Management board of Joint Stock Company “Olainfarm” hereby informs that the following additional items have been included in the agenda of [...]
Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June
17/05/2018
Oasmia Pharmaceutical AB announce that follow-up results from the completed phase III study with Apealea ® for treatment of ovarian cancer will be presented at the 2018 ASCO Annual Meeting in Chicago. Uppsala, Sweden, [...]
ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO
17/05/2018
SINGAPORE, May 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (Nasdaq: ASLN ), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan [...]
Annual General Meeting of EastPharma Ltd
17/05/2018
EASTPHARMA LTD. London, 17 May 2018 - EastPharma (EAST LI), today announces that following yesterday's Annual General Meeting of EastPharma Ltd, the Board of EastPharma Ltd is pleased to announce that the resolutions [...]
Terveystalo Plc: Terveystalo to acquire Attendo's healthcare operations in Finland
17/05/2018
Terveystalo Plc Stock Exchange Release 17 May 2018 at 09:00 EEST Terveystalo Plc ("Terveystalo") has today, on 17 May 2018, signed an agreement to acquire the Finnish healthcare operations of Attendo AB (publ) ("Attendo [...]
ESPERITE (ESP) : L1 Capital subscribes to the 18th tranche of investment today
17/05/2018
Amsterdam, The Netherlands - 17 May 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 18 th Tranche of EUR 400,000 is issued as a private placement of 40 convertible notes (the " [...]
ABLYNX ANNOUNCES WARRANT EXERCISE
17/05/2018
REGULATED INFORMATION GHENT, Belgium, 17 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an [...]
VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs
17/05/2018
Valneva Reports Strong Q1 Results and Continues to Advance Key R&D Programs Strong sales and EBITDA performance in Q1 2018 Product sales of €28.9 million in Q1 2018, representing 11.5% year on year growth, in line [...]
VALNEVA publie de très bons résultats financiers au premier trimestre, continue d'avancer sur ses programmes R&D clés
17/05/2018
Valneva publie de très bons résultats financiers au premier trimestre, continue d'avancer sur ses programmes R&D clés Forte performance des ventes et de l'EBITDA au T1 2018 Ventes de produits de €28,9 millions au T1 [...]
INNATE PHARMA : Preliminary activity observed of the combination of monalizumab and durvalumab in patients with colorectal cancer
17/05/2018
preliminary DATA from a phase I dose escalation and expansion study of monalizumab and Imfinzi ® (durvalumab) SHOW ANTI-TUMOR activity in COLORECTAL CANCER patients Preliminary activity observed in patients with [...]
INNATE PHARMA : Données préliminaires d'activité de la combinaison monalizumab et durvalumab dans le cancer colorectal
17/05/2018
DES DONN É ES PR É LIMINAIRES D'UN ESSAI DE PHASE I É VALUANT MONALIZUMAB ET IMFINZI® (DURVALUMAB) MONTRENT UNE ACTIVIT É ANTI-TUMORALE CHEZ DES PATIENTS PR É SENTANT UN CANCER COLORECTAL Activité préliminaire observée [...]
Biocartis Group NV: Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference
17/05/2018
PRESS RELEASE : 17 May 2018, 07:00 CEST Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference Mechelen, Belgium, 17 May 2018 - Biocartis Group NV (the 'Company' or 'Biocartis [...]
argenx to Present at Upcoming Investor Conferences
17/05/2018
May 17, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
17/05/2018
– PSA response rates in additional 20 mCRPC patients enrolled at Peter MacCallum Cancer Centre higher than previously reported for first group of 30 patients – – Company to host and webcast investor event featuring [...]
Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
16/05/2018
Company Release no. 12/2018 To: Nasdaq Copenhagen A/S Copenhagen, Denmark, 16 May 2018 Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 Correction: In the company [...]
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
16/05/2018
Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO ), an oncology-focused biopharmaceutical company, today [...]
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting
16/05/2018
Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy Poster Presentation to Include Data from a Total of over 50 Patients and Will Compare SD-101 at Two Dose Levels [...]
G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
16/05/2018
RESEARCH TRIANGLE PARK, N.C., May 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 [...]

Pages